Kidney Health Gateway
Back to all trials
Enrollment Closed
Interventional

The DUPLEX FSGS Study

Study of Sparsentan in FSGS  (DUPLEX)

Brief Description

*Enrollment is now closed. We will keep you updated on the results of this study as they are published. This clinical trial will determine the effectiveness of Sparsentan at reducing proteinuria in patients with primary FSGS.

Trial Physician / Study Coordinator

Jung Hee Kim

Email Phone 82220722303
Site Name

Seoul National University Hospital
101 Daehak-ro, Ihwa-dong, Jongno-gu, Seoul, South Korea

Sponsor

Travere Therapeutics

Study Drug

Sparsentan

Estimated enrollment

300

Estimated end date

December, 2022

If there is not a site for a clinical trial nearby, you can ask the study team about the possibility of travel reimbursements (i.e., paying you back for your travel costs). Alternatively, you can ask about the possibility of participating from home.
Find other locations for this trial:
Enrollment Closed
Interventional

The DUPLEX FSGS Study

Study of Sparsentan in FSGS  (DUPLEX)

Brief Description

*Enrollment is now closed. We will keep you updated on the results of this study as they are published. This clinical trial will determine the effectiveness of Sparsentan at reducing proteinuria in patients with primary FSGS.

Trial is for people with

Primary focal segmental glomerulosclerosis (FSGS)

Study Goal

To determine if sparsentan is works better than irbesartan at reducing proteinuria and reducing the rate of kidney damage caused by FSGS.

What is involved for the Patient?

Eligible participants will need to visit the study location 17 times. There will also be times they need to speak by telephone to study team personnel at the study location. The study will last 2 years and 3 months.

About the drug or intervention

Sparsentan is a dual-acting angiotensin receptor blocker and endothelin receptor antagonist.

Find other locations for this trial:
Seoul, South Korea
Frequently Asked Questions

Nephrotic Syndrome is not a disease itself, but rather a group of signs and symptoms that result from damage in the part of the kidney that filters blood (glomeruli).

Common symptoms include:

  • Foamy urine (called proteinuria) caused by protein “spilling” into the urine
  • Severe swelling in parts of the body, most noticeably around the eyes, hands, feet, and abdomen (called edema)
  • Weight gain due to a buildup of extra fluid
  • Fatigue
  • Loss of appetite
  • Low levels of protein in the blood (hypoalbuminemia)
  • Higher than normal fat and cholesterol levels in the blood (hyperlipidemia)

Nephrotic Syndrome can typically be diagnosed with a urine test.

Nephrotic Syndrome can be “primary” or “secondary” in nature.

Diseases that affect only the kidneys are called primary causes of Nephrotic Syndrome. Doctors often call these diseases “idiopathic,” which means that they arise from an unknown cause. Some of these diseases include:

  • Minimal Change Disease (MCD) – most common in children
  • Focal Segmental Glomerulosclerosis (FSGS)
  • Membranous Nephropathy (MN) – most common in adults
  • IgA Nephropathy (IgAN)

Secondary Nephrotic Syndrome is caused by an underlying, systemic condition like diabetes, lupus, HIV, and others.

The Kidney Health Gateway is a website owned and operated by NephCure Kidney International. The purpose of this website is to help patients with rare forms of primary Nephrotic Syndrome get connected to expert care and cutting-edge treatment options. By answering a few questions about you or your loved one’s condition, we can provide you with a list of clinical trials and/or expert doctors in your area.

If you have additional questions, please visit NephCure.org or email Info@NephCure.org.

 

See other frequently asked questions